Advertisement

Purpose:

A phase I study was done to evaluate the safety and pharmacokinetics of (L)-2-oxothiazolidine-4-carboxylate (OTZ). An ancillary objective was to compare the effects of treatment with 2 levels of OTZ to placebo on urinary oxalate excretion in healthy male subjects.

Materials and Methods:

Individuals underwent intravenous infusion of 70 (6) or 100 (6) mg./kg. body weight OTZ, or placebo for 2 hours at 4, 8-hour intervals. Urine was collected during the 12 hours before treatment, and at 0 to 4, 4 to 8, 8 to 24, 24 to 28, 28 to 32 and 32 to 48 hours after the initial infusion. Urine samples were assayed for creatinine, oxalate, citrate, sulfate, urate, phosphate and pH.

Results:

Urinary oxalate excretion relative to creatinine decreased significantly in the 100 mg./kg. dose group by 4.1 mg./gm. during the first 24 hours and by 4.6 mg./gm. in 24 to 48 hours compared to baseline values (p <0.05). Slight decreases of 0.9 and 1.1 mg./gm., respectively, in the 70 mg./kg. dose group, and 1.6 and 2.3 mg./gm., respectively, in the placebo group were observed. Oxalate excretion on day 2 in the 100 mg./kg. dose group was significantly less than that in the placebo group (p = 0.04). Urinary pH decreased and sulfate excretion increased with OTZ therapy.

Conclusions:

Treatment with 100 mg./kg. OTZ every 8 hours decreases urinary oxalate excretion in healthy men.

References

  • 1 : Primary hyperoxaluria. In: The Metabolic and Molecular Bases of Inherited Disease. Edited by . New York: McGraw-Hill Book Co.1995: 2385. Google Scholar
  • 2 : Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria.. New Engl. J. Med.1994; 331: 1553. Google Scholar
  • 3 : Pathways of hepatic oxalate synthesis and their regulation.. Amer. J. Physiol.1997; 272: 2289. Google Scholar
  • 4 : Peroxisomal oxidases and suggestions for the mechanism of action of insulin and other hormones.. Adv. Enzymol.1985; 57: 85. Google Scholar
  • 5 : A "chemical" concept for the therapy of glyoxylate-induced oxalurias.. Life Sci.1992; 50: 1597. Google Scholar
  • 6 : The inhibition of metabolic oxalate production by sulfhydryl compounds.. J. Urol.1991; 145: 1302. AbstractGoogle Scholar
  • 7 : Formation of the L-cysteine-glyoxylate adduct is the mechanism by which L-cysteine decreases oxalate production from glycollate in rat hepatocytes.. Biochem. J.1994; 302: 753. Google Scholar
  • 8 : Intracellular cysteine delivery system that protects against toxicity by promoting glutathione synthesis.. Proc. Natl. Acad. Sci.1982; 79: 6246. Google Scholar
  • 9 : Intracellular delivery of cysteine.. Meth. Enzymol.1987; 143: 313. Google Scholar
  • 10 : The efficacy of (L)-2-oxothiazolidine-4-carboxylate (OTC) and (L)-cysteine in reducing urinary oxalate excretion.. J. Urol.1994; 152: 2139. AbstractGoogle Scholar
  • 11 : Measurement of urinary oxalate and citrate by capillary electrophoresis and indirect ultraviolet absorbance.. Clin. Chem.1995; 41: 1297. Google Scholar
  • 12 : Genetic factors in calcium oxalate stone disease.. J. Urol.1995; 153: 301. AbstractGoogle Scholar
  • 13 : Some factors influencing the urinary excretion of oxalic acid in man.. Clin. Chim. Acta1969; 25: 1. Google Scholar
  • 14 : The influence of dietary factors on the risk of urinary stone formation.. Scan. Microsc.1993; 7: 1119. Google Scholar
  • 15 : Relationship of protein intake to urinary oxalate and glycolate excretion.. Kid. Int.1993; 44: 366. Google Scholar
  • 16 : Effects of protein, methionine, or chloride on acid-base balance and on cysteine catabolism. Amer. J. Physiol.1995; 269: E910. Google Scholar
  • 17 : Citrate and renal calculi: an update.. Min. Electr. Metab.1994; 20: 371. Google Scholar
  • 18 : Dietary oxalate and its intestinal absorption.. Scan. Microsc.1995; 9: 1109. Google Scholar
  • 19 : Oxalate-induced damage to renal tubular cells.. Scan. Microsc.1995; 9: 1097. Google Scholar
  • 20 : Importance of mild hyperoxaluria in the pathogenesis of urolithiasis-new evidence from studies in the Arabian peninsula.. Scan. Microsc.1993; 7: 391. Google Scholar
  • 21 Barditch-Crovo, P., Skowron, G., Lederman, M., Story, K., Webb, L. and Borum, P.: Human pharmacokinetic profile of oral Procysteine, L-2-oxothiazolidine-4-carboxylic acid. IXth International Conference on AIDS, Berlin, June 7-11, 1993 Google Scholar

From the Department of Urology, Bowman Gray School of Medicine, Winston-Salem, North Carolina and Transcend Therapeutics, Inc., Cambridge, Massachusetts.

Advertisement